Story
MaxCyte Shares Gain After Announcing Cell Therapy Licensing Deal with Genentech

Shares of MaxCyte Inc. (NASDAQ:MXCT) climbed 5.6% on Tuesday following the announcement of a strategic technology licensing agreement with Genentech. The deal provides the Roche Group subsidiary with access to MaxCyte's platform to support the development of its cell therapy programs.
Details of the Agreement
Under the terms of the partnership, Genentech will gain non-exclusive access to MaxCyte’s ExPERT GTx platform and other related technologies. This license covers multiple programs and is intended for *ex vivo* cell engineering applications across Genentech's research, clinical development, and manufacturing workflows.
MaxCyte's platform is designed to provide an integrated solution for cell therapy development, from early-stage discovery through to current Good Manufacturing Practice (cGMP) production. According to the announcement, the partnership allows Genentech to utilize complementary technologies for both cell engineering and analytical processes throughout the development lifecycle.
AdStrategic Importance and Outlook
The financial terms of the licensing deal were not disclosed. However, the partnership represents a significant validation of MaxCyte's technology by a major biopharmaceutical company.
Maher Masoud, President and CEO of MaxCyte, noted in a statement that the cell therapy field increasingly requires technology partners capable of supporting programs as they advance from research to manufacturing. He added that the agreement allows MaxCyte to provide broader support to Genentech by combining complementary capabilities in cell engineering and gene editing.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.